univers coverag
calendar event
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
sbla blincyto
medic meet american academi allergi asthma immunolog aaaai /wao
annual dialysi confer confer retrovirus opportunist infect
distribut manag associ hdma healthcar inform manag
system societi himss intern confer target anti-cancer therapi
downgrad mp fewer catalyst nt pt
bottom line downgrad lpnt mp lower pt quarter
show encourag improv volum trend especi ed inpati surgeri
asset class acquir hospit show promis broader volum trend improv
sever flu season polici standpoint repeal dsh cut fund rural medicar
extend along tax reform contempl guidanc consensu estim
lower ebitda estim mm mm respect top line
challeng delay margin expans strateg review point re-evalu rural
market trend possibl shift strategi emphasi altern access point urgent
 free stand ed unavail may make challeng amplifi invest
near term lower pt contempl ev ebitda multipl
upsid pt possibl believ challeng next twelv month given
challeng amplifi invest captur addit volum growth
quarter show encourag improv volum trend especi ed inpati surgeri
asset class acquir hospit show promis broader volum trend improv
sever flu season
tax polici tailwind reflect guidanc estim
guidanc high-end ebitda rang miss assum bp yoy margin contract
class show promis margin expans opportun eras
lower ebitda estim mm mm respect top line
challeng delay margin expans
lack even tax reform challeng strategi expand access
weak integr issu like push return
lower pt contempl ev ebitda multipl
dupix rx trend corrobor recent survey revenu upsid
bottom line recent medacorp survey dermatologist suggest consensu
estim regeneron op /sanofi sni op dupix underestim
potenti us adult atop dermat ad indic survey note new
analysi iqvia new brand prescript nbrx trend corrobor infer
suggest realiz revenu us sale adult ad indic could exceed
total consensu revenu estim product half
well new analysi trend dupix nbrx suggest stabl new us
adult ad patient per week seem like start treatment dupix forese futur
analysi suggest current treatment persist continu number us adult ad
patient dupix grow use
method estim dupix sale us adult ad indic
higher current global consensu current revenu run rate
per patient per month trend translat sale per month per
quarter per month per quarter revenu run rate
would contribut current consensu total sale dupix year well
iqvia analysi consist medacorp dermatologist survey conclud physician
expect treat mani adult ad patient year
bottom line last friday host call two high volum hip/kne specialist -- -one
mid-west one southeast -- -ahead american academi orthoped
surgeon aao annual meet new orlean discuss focus robot
penetr potenti knee surgeri -- -specialist think penetr industri yr surgeon
product/top area interest aao mako/robot new revis knee system technolog
tailor outpati surgeri custom implant total joint volum trend surgeon
respect practic -- -noth major call stabl trend gener flu lead surgeri delay
surgeon backlog robust cancel get fill immedi within
coverag aao confer relev op op op op
mp op overal feedback call mako robot bit tepid
would expect exist mako user us knee penetr forecast
heard past dilig link perhap neutral-to-slight neg
margin mako-driven knee share gain alreadi highli anticip
insid note includ detail takeaway discuss addit quick
summari key company-sponsor event schedul aao chart summar ortho robotics/
navig platform select presentations/podium present topic
zinbryta come end abbvi ambit ms
bottom line earlier morn announc world-wide discontinu
market long-act relaps multipl sclerosi product zinbryta daclizumab less
two year regulatori approv updat come result increas report
inflammatori advers event brain specif enceph meningo-
enceph addit advers event previous prompt initi
comprehens pharmacovigil investig european medicin agenc ema
safeti profil zinbryta alway liabil commerci viabil drug alreadi
clear black box warn sever liver injuri immun mediat disord disclosur
morn suggest decis remov zinbryta market
voluntari choic made manufactur given risk/benefit profil limit commerci
adopt drug due restrict label zinbryta compris million million
total revenu forecast respect collabor agreement
record us sale record sale outsid us
cumul report million ex-u sale zinbryta sinc approv
specif disclos us revenu like million total estim
zinbryta like encompass global ms market
doesnt matter much either compani outlook financi rais question
judgement behind invest daclizumab develop indic first place
follow announc remov zinbryta revenu forecast
also remov revenu zinbryta compani model result
immateri effect total revenu earn forecast compani
revenu ep exclud option expens estim pro forma spin
revenu mm dilut ep includ option expens present
head posit strength
sum-of-the-part weight average ev/ebitda multipl
bottom line deliv anoth good quarter head experienc
new manag team strong balanc sheet busi segment good place
oper new manag plan continu invest busi parallel
carri strateg review come month explor opportun drive sharehold
valu believ remain strong player store brands/over-the-count drug
market look better visibl longer term growth potenti updat model
reflect detail guidanc higher tax rate vs project lower
ep ep maintain market
perform rate pt stock look forward compani long-term strateg plan
present later year
busi continu build momentum detail long-term strategi later
e-commerc big part busi yet
consum healthcar america chca look flat y/i manag remain confid long-
term trend busi
reinvest consum healthcar intern chci reach upper teen oper margin
strong rx perform expect driven two larg product enter
limit read-through step-down management optimist pipelin
bottom line disclos morn donald bergstrom notifi
resign posit compani chief medic offic effect march
order pursu opportun spoke ceo anna protopapa note
dr bergstrom decis person relat mersana pipelin technolog accord
ms protopapa dr bergstrom take broader role head privat compani
focu earlier stage develop drug discoveri view also line
role prior join sni op global head translat medicin
focus earli stage develop mrsnha initi search new key updat
includ present first clinic data mid-year initi
tumor-specif dose-expans cohort year-end dose-escal compani anti-
phase on-going maintain op rate
recap platform set stage anoth catalyst-rich year
outperform market cap price price target methodolog dcf
discount rate termin gr rate
bottom line continu anoth catalyst-rich year data readout
anticip multipl divers clinic program one potenti pivot
catalyst trial bring compani closer ultim goal fda approv possibl
gener upsw stock price end strong suit clinic data
confirm safeti efficaci bardoxolon divers group mitochondri diseas
end compani report solid cash posit think carri
year catalyst therebi set stage even event
updat financi model reflect financi result reiter op pt
revenu mm ep present
weekli iqvia im trend dynam unchang ahead
bottom line note analyz iqvia formerli im script trend week end februari
harvoni epclusa vosevi mp mavyret mp zepati mp
hcv genvoya descovi odefsey juluca gsk mp hiv tagrisso azn mp lung
cancer imbruvica abbv/jnj op zydelig venclexta abbv/rhhbi nr hematolog
malign ibranc mp kisqali nv mp verzenio mp breast cancer xtandi
zytiga prostat cancer cabometyx mp renal cell carcinoma otezla celg
op plaqu psoriasi psoriat arthriti cosentyx nv plaqu psoriasi psoriat arthriti
ankylos spondyl taltz plaqu psoriasi tremfya plaqu psoriasi dupix sni
op/regn op eucrisa atop dermat kevzara sny/regn rheumatoid arthriti
tecfidera mp multipl sclerosi breo anoro incrus trelegi gsk/inva nr chronic
obstruct pulmonari diseas nucala gsk fasenra azn asthma praluent sny/regn
repatha mp entresto nv cardiovascular diseas trulic jardianc basaglar
toujeo soliqua sni tresiba xultophi nvo mp diabet contrav
orex nr obes ocaliva mp primari biliari cholang intrarosa mp
pleas see bodi report detail weekli iqvia script
bottom line report provid updat week end februari key gener
product watch
healthcar closer look
helix rais sequenc volum chang treatment
await close amneal transact
the-part weight average ev/ebitda multipl
fda panel expect posit outcom
updat program remain track sting data
outperform market cap price price target methodolog dcf
sum-of-part analysi assum discount termin growth rate
rais cinvanti estimate pt due unexpect windfal competitor
 methodolog dcf cash flow use wacc
 methodolog dcf base upon wacc termin growth rate
optim omav dose determin mito myopathi chang
recap oligomer modal could transform pt
 methodolog ev/ebitda ebitda
hcit distribut preview posit coordin vbc cautiou
 preview tax reform guidanc imp catalyst aet
medic suppli devic individu co preview cardio large-cap diversifi
expect submit new drug applic nda ali march prioriti
previous guid remain track expect advisori committe meet
adcom amikacin liposom inhal suspens ali refractori nontubercul
mycobacteri lung infect ntm caus mycobacterium avium complex
stock come investor question efficaci long-term durabl
approv believ fda panelist could view posit
extens studi data refractori ntm patient favor
believ discuss point may even consid possibl ali front-lin
therapi ahead guidelin base therapi fda-approv
addit ali data american thorac societi meet may
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
top-lin data expect two ph trial
high level convict derm topic acn program stem clinic valid
robust efficaci data ph iib studi highli power ph program pois
deliv definit result pt medacorp kol check support
strong reimburs access uptak prospect given uniqu on-target
mechan action
hyperhidrosi excess sweat pdufa probability-of-
top-lin result expect earli studi test rationally-
design formul commens bacteria resolv dysbiosi colon
manag believ dysbiosi primari cdi less sever effect restor
use lower number bacteri strain compar recurr cdi target
predict probabl success peak risk-adjust us gross
sale estim
believ posit result could enhanc appreci mcrb spore-bas approach
restor gut microbiom provid insight util synthet microbiom
april pdufa rubraca ovarian cancer
rubraca saw slow launch result competit posit platinum-
rubraca first parp inhibitor us approv line set brca patient
howev product tsro zejula azn mp lynparza surpass us
approv earlier broader line mainten set pressur rubraca
demand line
us approv rubraca broad line mainten indic pdufa date april
import growth driver product competit profil accord
physician survey
continu believ parp inhibitor address potenti larg market
opportun across sever tumor type beyond ovarian cancer among prostat
cancer repres particularli attract opportun pivot trial
well underway interim data expect
burosumab recent receiv posit eu chmp decis x-link
hypophosphataemia xlh believ encourag
burosumab adult xlh pt demonstr continu stabil serum phosphoru
level improv secondari endpoint stiff physic function pain
addit possibl disease-modifi characterist improv bone health
posit chmp decis provid credenc favor top-lin ph data initi
pdufa date fda advisori committe meet expect
storm phase ii studi selinexor penta-refractori multipl myeloma mm
full interim storm result selinexor low-dos dexamethason dex first
patient highlight drug single-ag activ difficult-to-treat patient --
management believ bode well approv probabl drug
prior data indic solid activ orr overal respons rate across
variou subgroup quad penta-refractori pt
top-lin storm ph ii data expand trial expect april
bold ph i/ii xlmtm crigler-najjar syndrom data
audent expect announc updat phase i/ii aspiro data x-link
myotubular myopathy/xlmtm well preliminari phase i/ii valen data crigler-
najjar syndrom
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
amicu enzyme-chaperon candid gener promis clinic
data thu far ph i/ii studi
management recent announc studi enrol addit pt gain insight
drug clinic profil
meanwhil observ studi potenti run-
upcom ph studi could provid import natur histori compar data
on-going ph i/ii studi
amicu meet regul updat
earli specul management believ rang outcom possibl
meet remain laser-focus get fastest approv pathway
model alreadi reflect earli launch possibl ascrib probabl success
 po market vs po launch
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi
sourc leerink research compani inform factset price prior day
fda adcom brief document oncolog drug sbla blincyto
fda adcom brief document gastrointestin drug panel snda
fda adcom oncolog drug sbla blincyto
fda adcom gastrointestin drug snda xeljanz ulcer coliti
fda adcom joint meet blood product microbiolog devic
fda adcom joint meet pediatr endocrinolog metabol drug
achondroplasia
brief document eversens pma medic devic adcom
fda adcom clinic chemistri clinic toxicolog devic panel
fda adcom peripher central nervou system drug
fda adcom endocrinolog metabol drug
pdufa akao plazomycin complic urinari tract infect bloodstream
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
american academi allergi asthma immunolog aaaai /wao
confer retrovirus opportunist infect
intern confer target anti-cancer therapi tat
healthcar inform manag system societi himss
american academi orthopaed surgeon aao
american colleg cardiolog cardiovascular
societi inherit metabol disord
societi toxicolog
intern confer alzheim parkinson diseas
 canadian academi patholog
intern confer ureagenesi defect
societi surgic oncolog
american academi osteopathi
societi gynecolog oncolog
intern societi amyloidosi
american colleg medic genet genom
intern societi heart lung transplant
societi american gastrointestin endoscop surgeon
american societi laser medicin surgeri
european associ studi liver
american societi cataract refract surgeri
american associ cancer research
molecular target tripl meet aacr-nci-eortc
hcit distribut preview posit coordin vbc cautiou
 preview tax reform guidanc imp catalyst aet
medic suppli devic individu co preview cardio large-cap diversifi
 aet creat new front healthcar outperform larsen
manag cvs-aet neutral ep wcg ci
gupt ana
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt
 state larg cap biotech sfo steadi goe
chang
 first apprais tax offer small benefit
 vertex alexion top pick
 ttr seri part handicap on-going tafamidi trial fac
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco anoth step forward cubist vabomer approv pt
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
view market
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut outlin possibl drug price polici
draconian fear
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
novob dc disappoint oral sema currenc price fear bake
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
 respit price yet friendli hill fda
could longer term
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 news patent decis one remind method use
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 outperform
 add cscc respons diseas boost /sni
 increas pt takeda collabor stock weak offer oppti
 atop dermat still without ped leerink
dupix derm survey
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 hiv survey rapid adopt biktarvi challeng
outlook gsk
 initi
 analyst event best idea
hcit distribut hospit hcit survey highlight shift analyt
healthcar leerink outlook
medic suppli devic survey direct posit
mute hope new indications/improv execut
major highlight medacorp lung cancer survey
focus nsclc
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
biopharma atop derm still without ped leerink dupi derm
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng
outlook gsk
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil
hcit distribut demand shift analyt effect use
major medacorp survey lung cancer posit
azn
medic devices-cardiolog tavr survey ew suggest upsid like
reflect share
medic suppli devic survey suggest pickup
 physician survey support nerlynx opp ty breast cancer pt
medic devic survey direct posit mute
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
outlook alpha opportun abound healthcar share
